Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group

Απλή σελίδα τεκμηρίου
dc.contributor.authorPapageorgiou, E. S.en
dc.contributor.authorTsirigotis, P.en
dc.contributor.authorDimopoulos, M.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorPapageorgiou, S.en
dc.contributor.authorEconomopoulos, T.en
dc.date.accessioned2015-11-24T19:29:42Z
dc.date.available2015-11-24T19:29:42Z
dc.identifier.issn0902-4441-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22991
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*administration & dosage/toxicityen
dc.subjectDeoxycytidine/administration & dosage/*analogs & derivativesen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLymphoma, B-Cell/drug therapyen
dc.subjectLymphoma, Large B-Cell, Diffuse/*drug therapyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectRemission Inductionen
dc.subjectSalvage Therapy/*methodsen
dc.subjectSurvival Analysisen
dc.subjectVinblastine/administration & dosage/*analogs & derivativesen
dc.titleCombination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Groupen
heal.abstractTo investigate the efficacy and toxicity of the combination of gemcitabine and vinorelbine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBL), 22 patients with relapsed or refractory DLBL were treated with gemcitabine 1000 mg/m2 and vinorelbine 30 mg/m2 on days 1 and 8 every 3 wk for a maximum of six cycles. Fourteen patients were considered chemosensitive while eight patients were considered chemoresistant to the last treatment regimen. All 22 patients were assessed for response to treatment. Three patients (14%) achieved complete remission and eight patients (36%) had partial remission of their disease, with an overall response rate of 50%. With a median follow up of 44 months, the median time to progression (TTP) for all patients was 8.1 months while the median overall survival (OS) was 12.9 months. Toxicity was minimal and all patients were treated on an outpatient basis. The combination of gemcitabine and vinorelbine is an effective and well-tolerated regimen for patients with relapsed of refractory DLBL.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1111/j.1600-0609.2005.00482.x-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16000128-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1111/j.1600-0609.2005.00482.x/asset/j.1600-0609.2005.00482.x.pdf?v=1&t=h0nicf9w&s=195eee210035d7b43f39aea1cc3603a3bec9bacb-
heal.journalNameEur J Haematolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2005-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ